Reversal of epigenetic silencing of AP-2alpha results in increased zinc uptake in DU-145 and LNCaP prostate cancer cells

Carcinogenesis

Volumn 32, Issue 12, 2011, Pages 1773-1781

  Makhov, Peter B ^a   Golovine, Konstantin V ^a   Kutikov, Alexander ^a   Canter, Daniel J ^a   Rybko, Vera A ^b   Roshchin, Dmitry A ^b   Matveev, Vsevolod B ^b   Uzzo, Robert G ^a   Kolenko, Vladimir M ^a  

^a FOX CHASE CANCER CENTER   (United States)

^b Cancer Research Center   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ACTIVATOR PROTEIN 2ALPHA; UNCLASSIFIED DRUG; ZINC; ZINC TRANSPORTER;

ARTICLE; CANCER CELL; CANCER TISSUE; DNA METHYLATION; DOWN REGULATION; EPIGENETICS; GENE EXPRESSION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE ADENOCARCINOMA; PROTEIN BINDING; PROTEIN HOMEOSTASIS;

AZACITIDINE; BASE SEQUENCE; CATION TRANSPORT PROTEINS; CELL LINE, TUMOR; CHROMATIN IMMUNOPRECIPITATION; DNA METHYLATION; DNA PRIMERS; EPIGENESIS, GENETIC; GENE SILENCING; HUMANS; MALE; PROMOTER REGIONS, GENETIC; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSCRIPTION FACTOR AP-2; TRANSCRIPTION, GENETIC; ZINC;

EID: 81855217387     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgr212     Document Type: Article

References (42)

1. Gaither, L. A. et al. (2001) The human ZIP1 transporter mediates zinc uptake in human K562 erythroleukemia cells. J. Biol. Chem., 276, 22258-22264.
2. Costello, L. C. et al. (2000) The intermediary metabolism of the prostate: a key to understanding the pathogenesis and progression of prostate malignancy. Oncology, 59, 269-282.
3. Ogunlewe, J. O. et al. (1989) Zinc and cadmium concentrations in indigenous blacks with normal, hypertrophic, and malignant prostate. Cancer, 63, 1388-1392.
4. Zaichick, V. et al. (1997) Zinc in the human prostate gland: normal, hyper-plastic and cancerous. Int. Urol. Nephrol., 29, 565-574.
5. Huang, L. et al. (2006) Decreased intracellular zinc in human tumorigenic prostate epithelial cells: a possible role in prostate cancer progression. Cancer Cell Int., 6, 10.
6. Franklin, R. B. et al. (2005) hZIP1 zinc uptake transporter down regulation and zinc depletion in prostate cancer. Mol. Cancer, 4, 32.
7. Desouki, M. M. et al. (2007) hZip2 and hZip3 zinc transporters are down regulated in human prostate adenocarcinomatous glands. Mol. Cancer, 6, 37.
8. Golovine, K. et al. (2008) Overexpression of the zinc uptake transporter hZIP1 inhibits nuclear factor-kappaB and reduces the malignant potential of prostate cancer cells in vitro and in vivo. Clin. Cancer Res., 14, 5376-5384.
9. Ushijima, T. et al. (2010) Aberrant DNA methylation in contrast with mutations. Cancer Sci., 101, 300-305.
10. Pierconti, F. et al. (2011) Epigenetic silencing of SOCS3 identifies a subset of prostate cancer with an aggressive behavior. Prostate, 71, 318-325.
11. Collard, R. L. et al. (2006) Methylation of the ASC gene promoter is associated with aggressive prostate cancer. Prostate, 66, 687-695.
12. McCabe, M. T. et al. (2006) Inhibition of DNA methyltransferase activity prevents tumorigenesis in a mouse model of prostate cancer. Cancer Res., 66, 385-392.
13. Makhov, P. et al. (2009) Transcriptional regulation of the major zinc uptake protein hZip1 in prostate cancer cells. Gene, 431, 39-46.
14. Livak, K. J. et al. (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods, 25, 402-408.
15. Douglas, D. B. et al. (2004) Hypermethylation of a small CpGuanine-rich region correlates with loss of activator protein-2alpha expression during progression of breast cancer. Cancer Res., 64, 1611-1620.
16. Ruiz, M. et al. (2001) Activator protein 2alpha transcription factor expression is associated with luminal differentiation and is lost in prostate cancer. Clin. Cancer Res., 7, 4086-4095.
17. Kelleher, S. L. et al. (2009) Zip3 (Slc39a3) functions in zinc reuptake from the alveolar lumen in lactating mammary gland. Am. J. Physiol. Regul. Integr. Comp. Physiol., 297, R194-R201.
18. Rishi, I. et al. (2003) Prostate cancer in African American men is associated with downregulation of zinc transporters. Appl. Immunohistochem. Mol. Morphol., 11, 253-260.
19. Ribarska, T. et al. (2010) Epigenetic inactivation of the placentally imprinted tumor suppressor gene TFPI2 in prostate carcinoma. Cancer Genomics Proteomics, 7, 51-60.
20. Guo, X. et al. (2010) Homeobox gene IRX1 is a tumor suppressor gene in gastric carcinoma. Oncogene, 29, 3908-3920.
21. Schayek, H. et al. (2010) Progression to metastatic stage in a cellular model of prostate cancer is associated with methylation of the androgen receptor gene and transcriptional suppression of the insulin-like growth factor-I receptor gene. Exp. Cell. Res., 316, 1479-1488.
22. Schorle, H. et al. (1996) Transcription factor AP-2 essential for cranial closure and craniofacial development. Nature, 381, 235-238.
23. Mitchell, P. J. et al. (1991) Transcription factor AP-2 is expressed in neural crest cell lineages during mouse embryogenesis. Genes Dev., 5, 105-119.
24. Orso, F. et al. (2007) The AP-2alpha transcription factor regulates tumor cell migration and apoptosis. Adv. Exp. Med. Biol., 604, 87-95.
25. Eckert, D. et al. (2005) The AP-2 family of transcription factors. Genome Biol., 6, 246.
26. Pena, P. et al. (1999) Activator protein-2 mediates transcriptional activation of the CYP11A1 gene by interaction with Sp1 rather than binding to DNA. Mol. Endocrinol., 13, 1402-1416.
27. Tan, C. C. et al. (2008) Transcription factor Ap2delta associates with Ash2l and ALR, a trithorax family histone methyltransferase, to activate Hoxc8 transcription. Proc. Natl Acad. Sci. USA, 105, 7472-7477.
28. Han, S. et al. (2007) Extracellular matrix fibronectin increases prostaglandin E2 receptor subtype EP4 in lung carcinoma cells through multiple signaling pathways: the role of AP-2. J. Biol. Chem., 282, 7961-7972.
29. Ruiz, M. et al. (2004) Activator protein 2alpha inhibits tumorigenicity and represses vascular endothelial growth factor transcription in prostate cancer cells. Cancer Res., 64, 631-638.
30. Zhu, C. H. et al. (2002) Dominant negative interference of transcription factor AP-2 causes inhibition of ErbB-3 expression and suppresses malignant cell growth. Breast Cancer Res. Treat., 71, 47-57.
31. Ren, Y. et al. (2001) Transcription factor AP-2 functions as a repressor that contributes to the liver-specific expression of serum amyloid A1 gene. J. Biol. Chem., 276, 17770-17778.
32. Kannan, P. et al. (1994) N-ras oncogene causes AP-2 transcriptional self-interference, which leads to transformation. Genes Dev., 8, 1258-1269.
33. Begon, D. Y. et al. (2005) Yin Yang 1 cooperates with activator protein 2 to stimulate ERBB2 gene expression in mammary cancer cells. J. Biol. Chem., 280, 24428-24434.
34. Sumigama, S. et al. (2004) Suppression of invasion and peritoneal carcinomatosis of ovarian cancer cells by overexpression of AP-2alpha. Oncogene, 23, 5496-5504.
35. Huang, S. et al. (1998) Loss of AP-2 results in downregulation of c-KIT and enhancement of melanoma tumorigenicity and metastasis. EMBO J., 17, 4358-4369.
36. Jean, D. et al. (1998) Loss of AP-2 results in up-regulation of MCAM/MUC18 and an increase in tumor growth and metastasis of human melanoma cells. J. Biol. Chem., 273, 16501-16508.
37. Heimberger, A. B. et al. (2005) Loss of the AP-2alpha transcription factor is associated with the grade of human gliomas. Clin. Cancer Res., 11, 267-272.
38. Lipponen, P. et al. (2000) Expression of activator protein 2 in prostate cancer is related to tumor differentiation and cell proliferation. Eur. Urol., 37, 573-578.
39. Marreiros, A. et al. (2005) KAI1 promoter activity is dependent on p53, junB and AP2: evidence for a possible mechanism underlying loss of KAI1 expression in cancer cells. Oncogene, 24, 637-649.
40. Dunwell, T. et al. (2010) A genome-wide screen identifies frequently methylated genes in haematological and epithelial cancers. Mol. Cancer, 9, 44.
41. Blute, M. L. et al. (2001) Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy. J. Urol., 165, 119-125.
42. Milon, B. C. et al. (2010) Ras responsive element binding protein-1 (RREB-1) down-regulates hZIP1 expression in prostate cancer cells. Prostate, 70, 288-296.